Beleave Inc. (CSE:  BE) (OTCQX:  BLEVF) is pleased to announce that it has closed a first tranche of the Company’s previously announced non-brokered private placement  (See press release dated June 8, 2018).  In conjunction with this first closing, 2,500,000 units of the Company were issued at a price of $2.00 per unit for gross proceeds of $5 million. The Company may, at its discretion, increase the size of the Non-Brokered Offering.

Each unit is comprised of one common share of the Company and one-half common share purchase warrant of the Company at a price of $2.00 per Unit. Each Warrant entitles the holder thereof to purchase one Common Share of the Company at an exercise price of $2.75 for a period of 24 months from the date of issuance of the Warrant, subject to accelerated expiry in the event that the ten-day volume weighted average price of the Common Shares on the Canadian Securities Exchange or other exchange or quotation system where the Company’s shares are listed and where a majority of the trading volume of the Common Shares occurs, equals or exceeds $3.00. Subject to customary closing conditions, including CSE approval, the Non-Brokered Offering is expected to have multiple tranches, with this first tranche closing today June 11, 2018.

“We’re thrilled to announce the first tranche from this new offering has closed,” said Beleave CEO Andrew Wnek. “This will further our goal to provide our patients and investors with meaningful services and great value.”

About Beleave

Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.